Small-cap companies, traders, investors, and businesses are invited to attend the 34th Annual ROTH Conference scheduled for March 13-15, 2022 be held at The Ritz Carlton, Laguna Niguel located in Dana Point, California. The conference will witness companies from a spectrum of diverse sectors, including consumer, energy, healthcare, industrial growth, metals & mining, sustainability, services, technology and more. Roth Conferences are one of the leading organizers of conferences for small-cap companies. Roth is a privately-owned investment banking firm dedicated to offering growth and networking opportunities to the small-cap public market. The previous years have shown some phenomenal responses from participants, sponsors and presenting companies. The event will feature approximately 450 participating companies and over 2,500 attendees will feature presentations from public and private companies in a variety of sectors. The event will showcase discussions, presentations, and keynotes by industry leaders and management teams on the latest trends, opportunities and prospects in the small-cap segment. The conference will begin at 7 am with Roth/CAF athletic activities, followed by conference registration, various activities that include meetings, chat presentations, and exhibits. Reputed leaders and thinkers of varied fields will put forth their valuable expertise and insights about the current and future trends of their respective fields. New businesses and startups can seek guidance and learn important industry strategies by attending these discussions and chats. After being organized as virtual events in 2020 and 2021, the 34th Annual Roth conference is being organized as an in-person event again this year. All safety and health protocols will be followed as per the federal, state, and local guidelines. The event will be held in a safe and secure environment. The agenda of the Roth Conference includes 1-on-1/small group meetings, analyst-selected fireside chats, thematic industry panels, and on-demand presentations. The event encourages networking opportunities for industries looking to establish long-term business connections and gain potential clients.  The Roth Conference experience promises to deliver entertainment and athletic charity events, along with business networking opportunities. An important addition to the conference is the New Issue Track, which will bring together newly-public companies, relatively unknown to investors. Many of these companies will be meeting with investors at the Roth Conference for the first time in a live format, offering:

• Company Presentations
• Analyst-Selected Fireside Chats
• Q&A Sessions
• 1-on-1 / Small Group Meetings
• Two Industry Panels

The Roth Cannabis Day & Reception will mark the closing event of the 34th Annual Roth Conference. At this event, shareholders and investors can gather pivotal information and guidance on how to make long-term profits from small-cap investments. They will also learn about future trends and the scope of expansion in their respective niches from experts, analysts, and influential personas. To learn more, please visit https://ibn.fm/GpjoC.

• Canadian-based clean energy solutions innovator FuelPositive Corp. is developing a means of producing and using ammonia for non-carbon polluting fuel
• Hydrogen has been touted as the ‘fuel of the future’, with the IEA predicting that hydrogen-based fuels will have to account for 30% of transportation fuels by 2050 to help the world achieve its zero emissions goals
• However, hydrogen has proven to be notoriously difficult to transport, given its highly volatile nature as well as its extremely low liquefying point (-253 degrees Celsius)
• Green Ammonia has emerged as both the best solution to transport and store hydrogen, as well as a renewable fuel source in its own right

Historically, passengers looking to take the 80-minute train journey linking the coastal town of Cuxhaven, Germany and Buxtehude, a commuter hub located just outside the city limits of Hamburg, would board the diesel train service run by German train operator, EVB. However, that all changed one Sunday morning in September 2018; on that day, the Coradia iLint, the world’s first hydrogen-powered passenger train, came into service on the nearly 100 kilometers of line running between the two destinations (https://ibn.fm/qXU3f). In addition to its efficient service – the train could achieve speeds of up to 140 kilometers per hour (86 miles per hour), the Coradia iLint marked a dramatic departure from the polluting trains of the past. The average diesel-powered train generates carbon emissions of as much as 27.5g CO2e per tonne kilometer (https://ibn.fm/8TLRl); the Coradia iLint, in turn, emits only steam and condensed water, with the latter element so pure, it can be used as drinking water. Although the environmental bona fides of hydrogen fuel cells and other pure hydrogen applications are undeniable – a 2021 International Energy Agency report forecast that to hit zero emissions by 2050, hydrogen-based fuels should account for nearly 30 percent of transport fuels by 2050 (https://ibn.fm/cuqld), the difficulty in effectively transporting and storing the fuel has hampered its mass adoption to date. Canadian-based clean energy solutions innovator, FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) has sought to resolve this conundrum through the development of its proprietary carbon-free green ammonia technology. Green ammonia, so called for its production process using renewable energy sources, has been shown to be one of the most effective mediums for the proper storage and transportation of energy from renewable power sources. Historically utilized to manufacture agricultural fertilizers, green ammonia has also been found to be one of the most efficient and low-cost means of transporting hydrogen. FuelPositive’s hydrogen-ammonia synthesizer technology provides the means of storing hydrogen as green ammonia for effective transportation and storage, with the option of easy conversion back to hydrogen for use in hydrogen fuel cells and other functions. Although pure hydrogen has often been touted as the ‘fuel of the future’, green ammonia has also been shown to be effective as an energy source in its own right; in fact, the gas has been found to boast a higher energy density, at 12.7 megajoules per liter than liquid hydrogen, at 8.5 MJ/L (https://ibn.fm/RFfT6). In other words, green ammonia can store and generate nearly 50 percent more energy per liter than the equivalent volume of liquid hydrogen. Moreover, liquid hydrogen must be cooled to minus 253 degrees Celsius to remain in liquid form, whereas green ammonia can become liquid at a mere minus 33 degrees Celsius, significantly decreasing the logistical challenges in transporting the fuel. As a result, green ammonia has already been touted as a vital potential fuel for the global shipping industry, with the latter accounting for approximately two to three percent of the world’s annual greenhouse gas emissions (https://ibn.fm/OaUAV). The IEA has revealed that green ammonia has an essential role to play in bringing global emissions to net zero, alongside biofuels and hydrogen. Jimmy Faria, a chemical engineer at the University of Twente in the Netherlands who has delved into the use of ammonia, forecast that green ammonia will continue to gain prevalence as carbon prices rise further: “I think ammonia is probably the future for liquid fuels” (https://ibn.fm/yz1Ks). With its technology well suited towards the production and transportation of green ammonia, FuelPositive Corp looks well positioned to capitalize on the ongoing global shift towards renewable energy sources and hydrogen-based fuels in particular. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• RWB has received all regulatory approvals and closed its acquisition of PharmaCo, a Michigan-based marijuana company
• This acquisition opens RWB to over 22 properties, including dispensaries and cultivation sites, giving it complete control of all its operations, from cultivating the product to selling it
• It marks a key milestone for the company and its shareholders as it continues to execute key components of its growth strategy
• For the 2022 calendar year, the company looks to extend its branded product lines, update its dispensaries, create supply chain efficiencies, and grow revenue and profitability

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) is slowly positioning itself to be one of the most prolific multi-state operators in cannabis and hemp-derived product lines in the United States. Its strategy has mainly consisted of acquisitions across states like Illinois and Massachusetts, with plans to expand to California and Florida. In what marks a significant milestone for RWB, it has announced having received all regulatory approvals and closing its acquisition of PharmaCo, a Michigan-based marijuana company. This acquisition expands RWB’s footprint within the state, having initially only had a single product line in this market- the Platinum Vape(R) brand (https://ibn.fm/fpiFt). “I am pleased to announce that we have closed on the PharmaCo acquisition and now control all aspects of our Michigan Operations,” noted Brad Rogers, the Chairman and Chief Executive Officer (“CEO”) of RWB. “This is a major milestone for RWB and its shareholders as we continue to execute key components of our growth strategy and build our house of brands across our core markets, as promised,” he added. The acquisition was made via RWB Michigan, LLC, a wholly-owned RWB subsidiary, at a consideration of 37 million RWB units. Each unit consisted of one common share and one series 2 convertible preferred share in the capital of RWB. The transaction also involved converting $30 million in previous advanced loans to PharmaCo into preferred shares in the company issued by RWB Michigan immediately before closing, giving the company 100% ownership of PharmaCo. This successful acquisition gives RWB access to 22 owned properties, including nine dispensaries and three cultivation sites in Glendale, Marquette, and Au Gres. RWB has also expanded its human resources within the State of Michigan by 180 employees and seeks to offer them competitive wages and incentives to share in the rewards of helping the company achieve its goals. “We welcome the many talented PharmaCo employees to the RWB team to continue their good work,” noted Mr. Rogers. “We value their contributions and feel it is important to pay competitive wages and provide key leaders and employees with a stake in the company so they can share in the rewards of helping RWB achieve its goals,” he added. Going forward, RWB looks to execute its initiatives that include extending its branded product lines, updating its dispensaries to heighten the customer experience, creating supply chain efficiencies, and growing revenue and profitability. This is possible given that the company now controls all Michigan operations, from growing the product to selling it. Michigan is one of the top cannabis markets in the United States, accounting for over $1.79 billion in sales in 2021 alone. “We are now in the driver’s seat on over 20 assets across Michigan- one of the largest and fastest-growing cannabis markets in the country,” reckoned Mr. Rogers. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• Report notes that global mergers and acquisition will continue into new year
• ACP performs months of due diligence before acquiring any properties
• Company exploring land acquisition, project development strategies for expanding operations to two more states this year

Mergers and acquisitions (M&A) appear to be a key component for companies looking to grow, with a recent 2022 Global M&A Trends Report indicating that M&A will continue in the new year (https://ibn.fm/BWtXR). Contending for first place in the U.S. cannabis industry, American Cannabis Partners (“ACP”) relies on proven strategies such as mergers and acquisitions to strengthen its position in a competitive market. “Through an analysis of M&A deal activity across seven to thirteen sectors, with breakdown for each region, the [Global M&A Trends Report] concludes that we should expect further, unprecedented global growth in 2022,” the article stated. “While the pandemic has continued to impact the wider market and M&A deal terms over the course of 2021, its impact has diminished from the preceding year. Across nearly all regions, practitioners agreed that due diligence was of paramount importance to doing deals in 2021.” Due diligence is a top priority for ACP; on its website, the company notes that it “performs months of due diligence before acquiring any properties. Our sights are set on listings in cannabis friendly states, cannabis population demand, agricultural zoning, available licenses, and market value. Land and equipment are purchased in full to keep American Cannabis Partners debt free, tangible, and liquid available. After acquisitions, cost-effective measures are taken to update and appraise properties to increase market value” (https://ibn.fm/HfswI). ACP CEO Stephen Jordan echoed this philosophy when he noted that the company focuses on “‘assets, assets, assets — and then build(s) the operations out,’ a rare approach in the cannabis industry where most companies create a product first and if something happens where they are unable to make that product, they go under” (https://ibn.fm/qZ0p0). The company recognizes that state and federal regulations can fluctuate wildly, but as a multistate operator, ACP can pivot within the fluctuations of each state’s laws. This focus on maintaining the ability to liquidate, move and survive is a fundamental strategy that allows American Cannabis Partners to protect its shareholders. ACP is in the process of exploring land acquisition and project development strategies for expanding operations to additional states this year. With a total of 12 cannabis licenses, including 20,000 square feet of cultivation licenses in California and 540,000 square feet of cultivation licenses along with one retail license in Michigan, ACP is committed to becoming a leader in the U.S. cannabis industry. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• Delic Holdings Corp is a leader in new medicines and treatments for a modern world with a focus on improving access to health benefits across the country through an integrated, scalable approach to meeting patients’ mental wellness needs
• Delic has built a three-pronged ecosystem that includes Ketamine Wellness Centers (“KWC”), the largest chain of wellness clinics providing ketamine treatments in the U.S.; Reality Sandwich and Meet Delic, media properties providing education on psychedelics; and DELIC Labs, a federally-authorized research facility
• The company’s CSO has spoken at a number of conferences on the importance of controlling the extraction production processes for cannabis, most recently at the annual Emerald Conference where he addressed artificial intelligence improvements
• U.S. health agencies have reported a four-fold increase in mental health concerns during the ongoing COVID-19 pandemic, demonstrating the rising need for responsive treatments

Delic Holdings (CSE: DELC) (OTCQB: DELCF) is showcasing the scientific talent driving its efforts to improve the production processes throughout the cannabis value chain for more effective use of the plant’s chemical properties, as demonstrated by DELIC Labs’ President and Chief Science Officer Dr. Markus Roggen’s presentation on Delic’s craft cannabis extraction research Feb. 28 at the annual Emerald Conference (https://ibn.fm/Ex7tl). Roggen’s presentation on “Artificial Intelligence for Craft Cannabis Products” highlights the lab’s experimental studies on the extraction behavior of solvents in developing a machine learning algorithm that can optimize extraction processes autonomously (https://ibn.fm/I9nnz), building on the company’s long-range efforts to increase control over production processes that were addressed by Roggen at CannMed a few years ago in a speech subsequently shared on YouTube (https://ibn.fm/ROCBg). DELIC Labs is a federally authorized psilocybin and cannabis research laboratory that dedicates its efforts to improve extraction, analytical testing, and chemical processes. The laboratory’s R&D solutions for product lines and new intellectual property (“IP”) serve as the engine for the company’s overall ecosystem. In addition to the scientific backbone of the ecosystem, Delic’s health operations aim to help people live better lives through the largest ketamine clinic chain in the United States, Ketamine Wellness Centers (“KWC”) operating a dozen locations strategically located in secondary cities to improve accessibility and reach and serve the greatest number of patients. The clinics have overseen thousands of mental health treatments to date, and the company plans to open 14 more clinics by mid-2023, according to a January corporate update (https://ibn.fm/aWT2E). The third component of Delic’s ecosystem is the company’s educational and promotional efforts through a variety of media outlets, including its Reality Sandwich digital magazine, a public education platform that provides psychedelic guides and news, streaming episodes on Delic Radio, and the company’s psychedelic wellness summit — Meet Delic — which drew more than 2,000 in-person attendees when it debuted in Las Vegas last fall (https://ibn.fm/7lLWX). Delic’s scalable approach to making psychedelic-based treatments a regular part of emotional health management is aimed at “giving people their best selves back.” During the advent of the COVID-19 pandemic, mental health concerns have only intensified. As noted in a Desert Sun report, 4 in 10 U.S. adults have reported symptoms of anxiety or depression during the pandemic — a four-fold increase from 2019. “While vaccines afford significant immunity from the worst physical effects of the virus, the trauma of widespread death, illness and isolation is considerably harder to inoculate against,” the report states (https://ibn.fm/Ft7dF). “At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S.,” Delic Co-founder and CEO Matt Stang stated during the corporate update. “There are 51.5 million Americans who have experienced a mental health condition and the ongoing pandemic has only exacerbated the crisis. We are seeing a strong demand for alternatives to current treatments with lasting outcomes and less side effects. … Delic is well-positioned for growth and profitability in 2022 and beyond.” For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• GreenBox will build the first banking-as-a-service initiative, catapulting the company into the same playing field as other major FinTech-driven brands
• CEO Fredi Nisan said the initiative will be a game changer for the company, expanding its capabilities and potential customer base, while also serving as a significant driver of revenue growth
• The partnership will provide additional services to existing clients on a single, seamless platform with a full suite of services that position the two companies to be a vertically-integrated full solution service

GreenBox POS (NASDAQ: GBOX), an emerging financial technology (FinTech) company that leverages proprietary security and token technology to build customized payment solutions for businesses, has announced entering a licensed partnership with Cross River. Cross River is a technology-driven infrastructure provider offering embedded financial solutions. The licensed partnership brings GreenBox closer to building compliant, cutting-edge blockchain ledger tokenized solutions for the diverse, evolving, and dynamic market worldwide (https://ibn.fm/y5Inb). Cross River is known for merging innovative state-of-the-art technology capabilities with the expertise of traditional banking, which is currently powering multiple leading FinTech companies across the United States. Through the partnership with Cross River, GreenBox will bring to realization its first banking-as-a-service initiative. This strategic move by GreenBox will catapult the company into the same playing field with other major FinTech-driven brands. “This was an important and necessary first step towards the launch of banking as a service which we believe will be a game-changer for GreenBox as it will radically expand our capabilities and the vast universe of potential customers, with a customer-inspired, technology-driven and combined offering,” GreenBox CEO Fredi Nisan said, talking about the partnership. “Not only will we eventually be able to offer all our existing merchant clients cutting edge banking services, but we can also open these solutions to strategic partnership and enterprises seeking white label solutions. We expect this to be a significant driver of revenue growth.” The infrastructure and payment rails provided by Cross River will enable GreenBox to open accounts (custodial, reserve, and operating accounts) for customers, which can be managed with a full suite of tools, all of them powered by Cross River. Resulting advantages include the potential creation of new channels to add customers, leading to great levels of revenue growth. Combining GreenBox technology with Cross River’s infrastructure will provide additional services to existing clients on a single, seamless platform with a full suite of services. “Joining forces with GreenBox highlights Cross River’s ability to do what we do best: empower innovative and responsible fintech companies to provide their customers with access to transparent, secure, and reliable financial solutions,” Cross River’s EVP and Head of FinTech Banking, Adam Goller, said. “We’re elated to be leading the way with GreenBox in advancing the digital finance landscape into a hassle-free, all-inclusive, and technology-centered experience for businesses and consumers alike.” Nisan also underlined that Cross River was the perfect partner to launch this ambitious initiative with, given their expertise in banking technology. “This represents yet another example of us executing against our master plan for expansion, with a trusted, tech-forward bank whose mission is aligned with our own. Together, we will be a disruptive force in the FinTech landscape, enabling the sustainable, long-term value our shareholders expect.” The initial phase of the partnership will serve as a foundation for banking-as-a-service solution. This offers customers a superior experience through a centralized hub under a user-friendly platform. The overall offering will roll out in multiple phases, delivering exceptional advantages like security, efficiency, and rapid transaction settlement across a wide range of capabilities. For more information, visit the company’s website at www.GreenBoxPOS.com. NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ibn.fm/GBOX

• The company recently announced a strategic private placement executed with agribusiness Nurture Healthy Foods to bring in just over $5 million in capital at $0.75 for M&A and general operations
• Plant-based consumer products brand builder Eat Well Investment Group Inc. is a growing investment company operating in North American markets
• Eat Well’s agreement with Nurture Healthy Foods includes an economic interest in Eat Well’s majority ownership of Amara Organic Foods, a growing manufacturer of plant-based baby foods
• The company’s products are also gaining increased distribution through companies such as Walmart, Whole Foods, Sprouts Farmer’s Market, Loblaws and HEB Grocery Company (H-E-B)

Vertically integrated plant-based foods investment company Eat Well Investment Group (CSE: EWG) (OTC: EWGFF), is securing new capital at $0.75 per Unit for M&A and general working activity, according to a recent announcement that notes not only a new round of private placement funding but also the sale of an interest in its portfolio company PataFoods, Inc. “This morning we shared with the markets that Nurture Healthy Food LLP has come in for a strategic private placement with us, approximately $5 million,” Eat Well CEO and Director Marc Aneed told Shoran Devi in a Feb. 15 interview with The Power Play (https://ibn.fm/vChpO). “The team at Nurture are like-minded to us. They are ESG (Environmental, Social and Governance factor)-driven, they are business builders and they are all about our mission, which is to feed families globally,” Aneed added. “This gives us strategic growth internationally through commercial, retail and distribution opportunities, as well as looking at deeper parts of their agribusiness portfolio and their plant-based solutions that we can bring to the world.” Eat Well Investment Group has customers in over 35 countries already, but the agreement with Nurture Healthy Food will help the company’s customer and distribution relationships “exponentially move into the future,” Aneed said. The company generated nearly $60 million (Canadian) in revenue last year during a breakout year when it acquired plant-based ingredients processor Belle Pulses and plant-based food creator Sapientia and added an OTC listing in the United States to its Canadian Stock Exchange profile. Eat Well expects to report top-line earnings between $90 million and $110 million by the end of this year. “We couldn’t be more excited to find ways to blueprint our distribution growth throughout South America, Latin America with their strength that they (Nurture Healthy Food) have today in retail,” Aneed said. Eat Well acquired 51 percent ownership of Pata Foods (dba baby food brand Amara Organic Foods) last year with an option to obtain up to 80 percent if it wishes. Amara reported 533 percent revenue growth during 2021 and was named Amazon’s top new release (https://ibn.fm/WmhXa). The economic interest in Amara that Eat Well sold to Nurture entitles Nurture to receive 8 percent of the net proceeds or other property received by Eat Well if a liquidation event occurs in regard to Amara, such as a merger or the sale of any portion of the company’s overall equity interest in Amara, as well as 8 percent of any dividend declared and paid by Amara to Eat Well (https://ibn.fm/OtQ9h). Eat Well’s growth strategy includes recent announcements that Amara will be distributed through over 400 Walmart stores in Canada and online through Walmart’s e-commerce platform, as well as through Loblaws’ Canadian stores nationwide and through 200 of food retailer HEB Grocery Company (H-E-B) stores in the United States. For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

• Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005
• This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compounds
• Mydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nausea
• The company is excited about this finding, terming it one of the many exciting drug discoveries it looks to share in the near term

Microdosing, the act of consuming a minimal dose of a psychedelic to benefit from what it offers without going through a psychoactive experience, has been gaining popularity recently. It has been lauded as a viable method of treating specific mental health conditions such as depression, anxiety, and attention-deficit/hyperactivity disorder (“ADHD”). However, more research is needed to confirm its safety and efficacy. One of the main issues that have been highlighted is the substantial medical risk involved with microdosing. Psilocybin, for instance, has shown a binding affinity to the 5-HT2B receptor, which is, in turn, linked to heart valve tissue fibrosis. As such, its consumption, over a long period, could present a patient with cardiovascular health concerns, a legitimate risk that ought to be considered (https://ibn.fm/O0mS4). In a significant move that remedies the situation, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced its latest drug discovery and its first of many for the new year, MYCO-005. Essentially a novel molecule in its family of psilocin analogs, MYCO-005 has proven to have potentially heart-safe microdose enabling properties while addressing the shortcomings and limitations associated with the first-generation compounds. “We are very excited about our MYCO-005 family of molecules,” noted Josh Bartch, the Chief Executive Officer (“CEO”) of Mydecine. “Not only have we made improvements to this second generation of compounds to specifically address concerns for medical use, like onset time and shelf stability, but now we believe we have also identified a microdosing compound that is safer than what’s currently available on the market,” he added. Mydecine’s patent-pending dermal route to administration offers more control over the drug while also potentially eliminating undesirable properties including, but not limited to, nausea. This is achieved by bypassing the digestive system. Going forward, the company seeks to explore this new feature and study its patent-pending skin permeation technology to produce a low-dosed, time-released patch that does not result in hallucinations for the patient. “This is one of the many exciting drug discoveries we look forward to sharing in the near term,” noted Mr. Bartch. This significant milestone for Mydecine proves its commitment to transforming the treatment of mental health and addiction disorders, particularly with psychedelics. It also shows its commitment to research and creating value for its shareholders. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Leveraging the versatility and benefits of its DehydraTECH(TM) technology, Lexaria is targeting multiple large market opportunities as it attempts to ensure it has multiple paths to success
• The technology aims to help companies offering oral drugs, supplements, and nicotine formulations to improve the effectiveness of their existing or planned products
• Lexaria has undertaken various studies whose findings show the benefits of DehydraTECH-processed products relative to controls
• The company intends to use the positive results from its studies to incrementally remove risks associated with commercialization and regulation

Lexaria Bioscience (NASDAQ: LEXX), a global drug delivery technology company transforming existing consumer products and medication by increasing their bioavailability, speed of onset, and brain absorption, is currently targeting multiple large market opportunities, ranging from cardiovascular drugs, antivirals, human hormones, and phosphodiesterase inhibitor (“PDE5 inhibitor”) formulations to nicotine replacement, and cannabidiol (“CBD”). “We are currently pursuing or investigating several large market opportunities, the smallest of which is currently generating over $10 billion in annual revenue. In many of these markets, growth is expected to be significant over the next several years. The Lexaria management team is trying to ensure that we have multiple paths to success,” Lexaria CEO Chris Bunka wrote in a January 27 annual update to its stakeholders (https://ibn.fm/0zK6O). The company’s multifaceted operational approach leverages its versatile and disruptive DehydraTECH(TM) technology, which is currently protected by a total of 23 granted patents worldwide. Designed specifically for delivering fat-soluble drugs and active pharmaceutical ingredients, DehydraTECH pairs the active ingredients with a fatty acid oil, such as high oleic sunflower oil. It then applies the resultant compound to food or carrier particles such as sorbitol or gum Arabic before a dehydration synthesis procedure is performed. The final step entails rendering the product as powder or liquid (https://ibn.fm/Pzile). “Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products,” the company’s website reads. And multiple studies have supported this statement. Most recently, Lexaria announced positive results from an animal study, PDE5-A21-1, investigating DehydraTECH processing of PDE5 inhibitor sildenafil for potential application in the management of erectile dysfunction. Conducted at a US-based, third-party independent laboratory, the study involved 20 male Sprague-Dawley rats, half of which were treated with one dose of the DehydraTECH-sildenafil, with the rest receiving generic concentration-matched, control-sildenafil formulation. The PDE5-A21-1 study showed that DehydraTECH technology delivered 74% more sildenafil into the bloodstream on average than the control just four minutes after dosing. After another three minutes, the DehydraTECH-sildenafil formulation reached an average blood level higher than the control formulation achieved at any point during the study. Further, the DehydraTECH-sildenafil reached a maximum concentration in the bloodstream (“Cmax”) that was approximately 70% higher and at a 25% faster rate than generic sildenafil control formulation. With the common complaint among many sildenafil users being that it is slow to act, the findings of the PDE5-A21-1 study could usher a new dispensation as regards the development of better and faster-acting sildenafil oral formulations. The results supported further investigation involving a larger number of animals. Overall, Lexaria aims to leverage positive results from such studies to journey step by step toward removing risks associated with commercialization and regulation. Eventually, the company says, with enough positive data, the formula will tilt in its direction. “Our R&D focus for 2021 was to investigate DehydraTECH-CBD for possible hypertension and heart disease applications; to further our knowledge of DehydraTECH-nicotine as a replacement for damaging and deadly lung-based absorption methods; and to learn whether DehydraTECH would be compatible with antiviral drugs. We were successful in each of these primary areas of investigation,” Bunka wrote. Looking ahead to 2022, Lexaria plans to launch three major studies between March and April: the human sublingual/buccal tissue study (oral nicotine), the animal seizure study (“CBD”), and its most ambitious study yet, the 6-week human hypertension study (“CBD”). The goal of these three studies is to generate sufficient data to support either regulated IND-type applications or influence corporate partnerships. At the same time, Lexaria will also be conducting several smaller studies throughout the year and will update shareholders when appropriate. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• PlantX recently added a new YouTube educational series to its channel- “Medically Speaking”
• This new series will complement the company’s growing body of resources, including podcasts, blogs, and articles posted on its website
• Mr. Sean Dollinger, the Founder of PlantX, recognizes that there is a growing need and demand for engaging plant-based educational opportunities
• The company seeks to capitalize on this education-oriented approach to empower its audience and help them overcome barriers to change in their journey towards adopting a plant-based lifestyle

It is estimated that around 2 billion people globally live on a largely meat-based diet, while 4 billion thrive on a mostly plant-based diet. Between 2014 and 2017, there was a 500% increase in the number of vegan consumers in the United States. Additionally, there was an 11% increase in retail sales of plant-based foods from 2018 to 2019 (https://ibn.fm/liSI4). These figures show a growing demand for plant-based products and the increasing adoption of a plant-based lifestyle. PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), an enterprise that focuses on everything plant-based, recognizes this growing trend and looks to capitalize on it going forward. So far, PlantX offers more than 5,000 plant-based products to customers across North America. Additionally, it provides meal and indoor plant deliveries for an all-around experience. The company’s goal is to become the digital face of the plant-based community, covering everything from retail to community-building efforts, new product offerings, and, most importantly, education. PlantX is banking on an education-oriented approach to not only retain its existing customers but also attract new ones. Its educational content, so far, covers the value of plant-based living, cooking recipes, and podcasts that feature experts in the industry. The company is confident that with this ever-growing body of content, its audience will get access to all the necessary knowledge needed to achieve their plant-based goals. “We have seen a tremendous global shift to plant-based diets in recent years, and this trend continues to rise. As the interest in plant-based diets increases, so does the need and demand for engaging plant-based educational opportunities,” noted Sean Dollinger, Founder of PlantX (https://ibn.fm/S61lh). The company’s most recent addition to its YouTube educational series, “Medically Speaking,” seeks to provide evidence-based information to bridge knowledge gaps and clarify potential questions in the plant-based space. This new series also aims to offer creative solutions to overcome plant-based challenges, with insights from trusted healthcare professionals. This approach also translates to regularly updated blogs and articles on its website, intended to offer consumers value and uplift the plant-based community. “Whether you follow a plant-based lifestyle or you’re a flexitarian, you can count on our news to guide you on this journey,” states its website (https://ibn.fm/TXD6Z). Going into 2022, PlantX hopes to win big with its education-oriented approach. Mr. Dollinger and the rest of the company’s leadership are confident that this method will bear fruit as time progresses. The company has achieved a lot in empowering people and helping them overcome barriers to change with its content so far. It hopes to take things even further in this new year and impact even more lives while at it. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF